Deprescribing anticholinergic and sedative medicines: A feasibility study in residential aged care facilities
- Conditions
- OverprescriptionPolypharmacyInappropriate prescribingPublic Health - Health service research
- Registration Number
- ACTRN12616000721404
- Lead Sponsor
- Professor Steve Duffull, Dean of the Pharmacy school
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 150
1.Aged 65 years or older
2.A drug burden index (DBI) of 0.5 or greater
3.Taking at least one anticholinergic medication from the reference anticholinergic list published by Salahudeen et al. or one sedative medicine as listed by Hilmer et al.
1.Limited life expectancy: resident is receiving palliative care or their life expectancy is 3 months or less, based on Holmes life expectancy calculator
2.Residents admitted for hospice care (short-duration of stay of less than 4 weeks)
3.Severe dementia: residents’ with a score on the Mini-mental State Examination test (MMSE) < 10
4.Resident’s not prescribed any anticholinergic medicines.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in the participants’ drug burden index (DBI) 6 months after the deprescribing intervention has been implemented. [6 months ]
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.